Science News
from research organizations

Research may explain how foremost anticancer 'guardian' protein learned to switch sides

Date:
July 29, 2014
Source:
Cold Spring Harbor Laboratory
Summary:
A cellular program that evolved over eons to heal wounds may have been hijacked by mutant p53 proteins to enable cancers to spread out of control. This protein normally comes to the fore when healthy cells sense damage to their DNA caused by stress, such as exposure to toxic chemicals or intense exposure to the sun's UV rays. If the damage is severe, p53 can cause a cell to commit preprogrammed cell-death, or apoptosis. Mutant versions of p53 that no longer perform this vital function, on the other hand, are enablers of many different cancers.
Share:
       
FULL STORY

The protein p53-psi, a variant of the well-known anti-cancer guardian protein p53, can reprogram cells to "switch sides" and acquire pro-metastatic features. Pro-metastatic cells naturally expressing p53-psi are seen in LEFT panel. On RIGHT, when p53-psi is silenced, these cells reacquire the characteristics of non-metastatic cells.
Credit: Sordella lab, Cold Spring Harbor Laboratory

Researchers at Cold Spring Harbor Laboratory (CSHL) have discovered a new function of the body's most important tumor-suppressing protein. Called p53, this protein has been called "the guardian of the genome." It normally comes to the fore when healthy cells sense damage to their DNA caused by stress, such as exposure to toxic chemicals or intense exposure to the sun's UV rays. If the damage is severe, p53 can cause a cell to commit preprogrammed cell-death, or apoptosis. Mutant versions of p53 that no longer perform this vital function, on the other hand, are enablers of many different cancers.

Cancer researcher Dr. Raffaella Sordella, a CSHL Associate Professor, and colleagues, today report in Proceedings of the National Academy of Sciences the discovery of a p53 cousin they call p53-psi (the Greek letter "psi"). It is a previously unknown variant of the p53 protein, generated by the same gene, called TP53 in humans, that gives rise to other forms of p53.

Sordella and colleagues observed that p53-psi, when expressed, reduces the expression of a molecular glue called E-cadherin, which normally keeps cells in contact within epithelial tissue, the tissue that forms the lining of the lung and many other body organs. This is accompanied by expression of key cellular markers associated with tumor invasiveness and metastatic potential. (These are markers of EMT, or epithelial-to-mesenchymal transition.) Consistently, Sordella and her team found levels of p53-psi to be elevated in early-stage lung tumors with poor prognosis.

Careful investigation revealed that p53-psi generates pro-growth effects by interacting with a protein called cyclophillin D (CypD), at the membrane of the cell's energy factories, the mitochondria, and by spurring the generation of oxidizing molecules called reactive oxygen species (ROS).

p53-psi was found by the team to be inherently expressed in tumors but also in injured tissue. "This is intriguing," Sordella says, "because generation of cells bearing characteristics of those seen in wound healing has been seen previously, in tumors."

It is possible, Sordella says, that more familiar p53 mutants associated with tumor growth and metastasis may have "hijacked" those abilities from the program used by p53-psi; to promote healing during tissue injury. A cellular program, in other words, that evolved over eons to heal may have been hijacked by mutant p53 to enable cancers to spread out of control.

The team is currently investigating p53-psi in wound healing to help clarify its role. Confirmation would lend support to the theory that mutant p53 hijacks that function to help advance pro-metastatic processes in cancer.


Story Source:

The above post is reprinted from materials provided by Cold Spring Harbor Laboratory. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Senturk, Z. Yao, M. Camiolo, B. Stiles, T. Rathod, A. M. Walsh, A. Nemajerova, M. J. Lazzara, N. K. Altorki, A. Krainer, U. M. Moll, S. W. Lowe, L. Cartegni, R. Sordella. p53  is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proceedings of the National Academy of Sciences, 2014; DOI: 10.1073/pnas.1321640111

Cite This Page:

Cold Spring Harbor Laboratory. "Research may explain how foremost anticancer 'guardian' protein learned to switch sides." ScienceDaily. ScienceDaily, 29 July 2014. <www.sciencedaily.com/releases/2014/07/140729123836.htm>.
Cold Spring Harbor Laboratory. (2014, July 29). Research may explain how foremost anticancer 'guardian' protein learned to switch sides. ScienceDaily. Retrieved July 29, 2015 from www.sciencedaily.com/releases/2014/07/140729123836.htm
Cold Spring Harbor Laboratory. "Research may explain how foremost anticancer 'guardian' protein learned to switch sides." ScienceDaily. www.sciencedaily.com/releases/2014/07/140729123836.htm (accessed July 29, 2015).

Share This Page: